Colorectal Cancer: Page 2

CMS extends Signatera molecular disease test coverage
The decision took effect in April, and adds to existing Medicare coverage for the test for colorectal cancer and for pan-cancer immunotherapy monitoring, the company said.
July 17, 2022
2020 04 30 21 13 0442 Medicare Puzzle 400
Exact Sciences supports CMS screening policy changes
The CMS Calendar Year 2023 Physician Fee Schedule proposal considers follow-up colonoscopy to an at-home test as a preventative service. The rule would eliminate all costs to Medicare patients for a follow-up colonoscopy following a positive at-home colorectal cancer screening test.
July 10, 2022
2019 09 23 17 18 0797 Colon Intestine 400
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Guardant releases colorectal cancer blood test
In a validation effort using 309 patient samples (including 92 with colorectal cancer), the Shield test showed a sensitivity of 91% and a specificity of 92% for detecting colorectal cancer. It is intended for adults 45 years and older who are not current with screening recommendations, are asymptomatic, and are at average risk for the disease.
May 1, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Guardant wins new clearances in Japan for liquid biopsy test
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
2022 03 08 19 56 8772 Clearance Stamp 400
Most Popular
COVID-19 immune response strengthens over time: Study
Cardiovascular disease deaths undergo largest single-year increase since 2015
California sisters plead guilty in $7.5M Medicare fraud involving phlebotomy services
Study: One-third of ‘mostly young and healthy’ people develop long COVID symptoms
Roche launches COVID-19 PCR test to detect fast-spreading XBB.1.5 Omicron subvariant
AI tool makes speedy gene-editing possible, offers alternative to CRISPR
No advantage for ctDNA assay for monitoring colorectal cancer
A research team led by Dr. Marwan Fakih at the City of Hope Comprehensive Cancer Center in Duarte, CA, sought to determine which technique is superior in identifying residual disease and early cancer recurrence: Natera's Signatera ctDNA assay or CT scans and a CEA blood draw. They found the National Comprehensive Cancer Network's (NCCN) current standard of care (CT scans and a CEA blood draw) had higher sensitivity than the assay (JAMA Network Open, March 8, 2022, Vol. 5:3, e221093).
March 9, 2022
2022 03 10 00 18 3072 2022 03 10 Ct Dna Fakih Marwan 400 20220310005244
FDA clears Foundation Medicine's companion diagnostic
Characterizing these tumors helps clinicians identify patients who could benefit from immunotherapy such as Keytruda, a humanized antibody used in cancer immunotherapy, the company said. MSI-H status is a defining feature of colorectal, endometrial, and gastrointestinal cancers.
February 22, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Guardant touts studies on liquid biopsy tests at ASCO meeting
Data from a large, prospective, observational study shows that Guardant Reveal can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time greater than six months when performed after curative intent surgery for stage II-III colorectal cancer, Guardant said.
January 19, 2022
2020 06 01 18 51 2022 Cancer Lung 400
Natera to expand into early cancer detection
In November 2021, Natera announced exclusive access from Aarhus University to a biobank of up to 40,000 prospectively collected colorectal cancer screening samples for the development and validation of Natera's early cancer detection products. The database of samples is expected to help accelerate the introduction of Natera's products to market and potentially support key commercial milestones, the company said.
January 5, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Lab Genomics, Canexia secure MolDX coverage for DNA assay
The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.
November 1, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
DiaCarta touts results from ColoScape assay in colon cancer
DiaCarta's ColoScape xenonucleic acid (XNA)-mediated quantitative real-time polymerase chain reaction clamping assay targets 19 mutations in a panel of genes linked with early precancerous colorectal cancer lesions. ColoScape detects mutant cell-free DNA (cfDNA) mutations with high sensitivity, according to the results.
October 26, 2021
2019 10 01 18 58 9423 Colon2 400
Previous Page
Page 2 of 4
Next Page